Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.
Curr Rheumatol Rep
; 16(11): 459, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25315196
ABSTRACT
Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Doenças Cardiovasculares
/
Fatores Biológicos
/
Antirreumáticos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article